Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2006 1
2007 1
2009 1
2010 2
2011 5
2012 5
2013 4
2014 2
2015 3
2016 3
2017 3
2018 2
2019 4
2020 3
2021 6
2022 1
2023 2

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
The role of the ALK receptor in cancer biology.
Hallberg B, Palmer RH. Hallberg B, et al. Ann Oncol. 2016 Sep;27 Suppl 3:iii4-iii15. doi: 10.1093/annonc/mdw301. Ann Oncol. 2016. PMID: 27573755 Free article. Review.
This review summarises the latest research on the receptor tyrosine kinase ALK, and how this information can guide the management of patients with cancer that is ALK-positive. ...This emphasises the need to tailor the sequence of ALK TKIs according to the …
This review summarises the latest research on the receptor tyrosine kinase ALK, and how this information can guide the management of …
Targeting anaplastic lymphoma kinase in neuroblastoma.
Umapathy G, Mendoza-Garcia P, Hallberg B, Palmer RH. Umapathy G, et al. Among authors: hallberg b. APMIS. 2019 May;127(5):288-302. doi: 10.1111/apm.12940. Epub 2019 Apr 3. APMIS. 2019. PMID: 30803032 Free PMC article. Review.
An impressive array of tyrosine kinase inhibitors (TKIs) that act to inhibit ALK have been FDA approved for use in ALK-driven cancers. ALK TKIs bind differently within the ATP-binding pocket of the ALK kinase domain and have been associated with differ …
An impressive array of tyrosine kinase inhibitors (TKIs) that act to inhibit ALK have been FDA approved for use in ALK-driven …
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.
Hallberg B, Palmer RH. Hallberg B, et al. Nat Rev Cancer. 2013 Oct;13(10):685-700. doi: 10.1038/nrc3580. Nat Rev Cancer. 2013. PMID: 24060861 Review.
The common activation of ALK has led to the use of the ALK tyrosine kinase inhibitor (TKI) crizotinib in a range of patient populations and to the rapid development of second-generation drugs targeting ALK. In this Review, we discuss our current understanding …
The common activation of ALK has led to the use of the ALK tyrosine kinase inhibitor (TKI) crizotinib in a range of patient po …
Anaplastic lymphoma kinase in human cancer.
Schonherr C, Hallberg B, Palmer R. Schonherr C, et al. Among authors: hallberg b. Crit Rev Oncog. 2012;17(2):123-43. doi: 10.1615/critrevoncog.v17.i2.10. Crit Rev Oncog. 2012. PMID: 22471704 Review.
The anaplastic lymphoma kinase (ALK) receptor tyrosine kinase is now implicated in a wide range of human cancers. Results from recent clinical trials with ALK inhibitors provide promise for patients harboring oncogenic ALK lesions. ...
The anaplastic lymphoma kinase (ALK) receptor tyrosine kinase is now implicated in a wide range of human cancers. Results from recent …
FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase.
Guan J, Umapathy G, Yamazaki Y, Wolfstetter G, Mendoza P, Pfeifer K, Mohammed A, Hugosson F, Zhang H, Hsu AW, Halenbeck R, Hallberg B, Palmer RH. Guan J, et al. Among authors: hallberg b. Elife. 2015 Sep 29;4:e09811. doi: 10.7554/eLife.09811. Elife. 2015. PMID: 26418745 Free PMC article.
Vertebrate ALK has been considered to be an orphan receptor and the identity of the ALK ligand(s) is a critical issue. Here we show that FAM150A and FAM150B are potent ligands for human ALK that bind to the extracellular domain of ALK and in addition t …
Vertebrate ALK has been considered to be an orphan receptor and the identity of the ALK ligand(s) is a critical issue. Here we …
ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation.
Borenäs M, Umapathy G, Lai WY, Lind DE, Witek B, Guan J, Mendoza-Garcia P, Masudi T, Claeys A, Chuang TP, El Wakil A, Arefin B, Fransson S, Koster J, Johansson M, Gaarder J, Van den Eynden J, Hallberg B, Palmer RH. Borenäs M, et al. Among authors: hallberg b. EMBO J. 2021 Feb 1;40(3):e105784. doi: 10.15252/embj.2020105784. Epub 2021 Jan 7. EMBO J. 2021. PMID: 33411331 Free PMC article.
ALK is activated by the ALKAL2 ligand located on chromosome 2p, along with ALK and MYCN, in the "2p-gain" region associated with NB. ...Therefore, we tested whether ALKAL2 ligand could potentiate NB progression in the absence of ALK mutation. We show that ALK …
ALK is activated by the ALKAL2 ligand located on chromosome 2p, along with ALK and MYCN, in the "2p-gain" region associated wi …
ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression.
Chuang TP, Lai WY, Gabre JL, Lind DE, Umapathy G, Bokhari AA, Bergman B, Kristenson L, Thorén FB, Le A, Doebele RC, Van den Eynden J, Palmer RH, Hallberg B. Chuang TP, et al. Among authors: hallberg b. Proc Natl Acad Sci U S A. 2023 Feb 21;120(8):e2216479120. doi: 10.1073/pnas.2216479120. Epub 2023 Feb 15. Proc Natl Acad Sci U S A. 2023. PMID: 36791109 Free PMC article.
Anaplastic lymphoma kinase (ALK) fusion variants in Non-Small Cell Lung Cancer (NSCLC) consist of numerous dimerizing fusion partners. ...Therefore, understanding the oncogenic signaling networks driven by different ALK fusion variants is important. To do this, we d …
Anaplastic lymphoma kinase (ALK) fusion variants in Non-Small Cell Lung Cancer (NSCLC) consist of numerous dimerizing fusion partners …
Anaplastic lymphoma kinase: signalling in development and disease.
Palmer RH, Vernersson E, Grabbe C, Hallberg B. Palmer RH, et al. Among authors: hallberg b. Biochem J. 2009 May 27;420(3):345-61. doi: 10.1042/BJ20090387. Biochem J. 2009. PMID: 19459784 Free PMC article. Review.
Recent reports of the EML4 (echinoderm microtubule-associated protein like 4)-ALK oncoprotein in NSCLC (non-small cell lung cancer), together with the identification of activating point mutations in neuroblastoma, have highlighted ALK as a significant player and tar …
Recent reports of the EML4 (echinoderm microtubule-associated protein like 4)-ALK oncoprotein in NSCLC (non-small cell lung cancer), …
Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells.
Cervantes-Madrid D, Szydzik J, Lind DE, Borenäs M, Bemark M, Cui J, Palmer RH, Hallberg B. Cervantes-Madrid D, et al. Among authors: hallberg b. Sci Rep. 2019 Dec 18;9(1):19353. doi: 10.1038/s41598-019-55060-7. Sci Rep. 2019. PMID: 31852910 Free PMC article.
Continuous development of ALK inhibitors has resulted in the third generation inhibitor repotrectinib (TPX-0005), which targets the active kinase conformations of ALK, ROS1 and TRK receptors. ...Neuroblastoma cell lines were treated with repotrectinib to investigate …
Continuous development of ALK inhibitors has resulted in the third generation inhibitor repotrectinib (TPX-0005), which targets the a …
Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC.
Bokhari AA, Lai WY, Le AT, Gabre JL, Chuang TP, Fransson S, Bergman B, Djos A, Chen N, Martinsson T, Van den Eynden J, Doebele RC, Palmer RH, Hallberg B, Umapathy G. Bokhari AA, et al. Among authors: hallberg b. Lung Cancer. 2022 Sep;171:103-114. doi: 10.1016/j.lungcan.2022.07.010. Epub 2022 Jul 25. Lung Cancer. 2022. PMID: 35933914 Free article.
Variants 1 and 3 are the most common EML4-ALK variants expressed in ALK-positive NSCLC, and currently cell lines representing these EML4-ALK variants are limited. ...Whole-genome sequencing was performed to determine the presence of EML4-ALK fusion and …
Variants 1 and 3 are the most common EML4-ALK variants expressed in ALK-positive NSCLC, and currently cell lines representing …
46 results